Abbott, FDA Warn About Possible Overdose of Antiretroviral Kaletra in Children
August 15, 2007
FDA and Abbott Laboratories are warning health care providers to be cautious in prescribing Abbott's antiretroviral drug Kaletra to children after the death of an infant who received an accidental overdose of the drug, the AP/Forbes reports. Abbott in an Aug. 6 letter, which was posted on FDA's Web site on Tuesday, said that children should receive no more than a five milliliter dose of Kaletra. The infant who died received a 6.5 milliliter dose (AP/Forbes, 8/14). According to Dow Jones/CNNMoney.com, the infant received an oral solution of Kaletra, which contains 80 milligrams of lopinavir and 20 milligrams of ritonavir per milliliter. Kaletra also is available in tablet form.
HIV/AIDS Programs' Limited Time Spans, Other Issues Hinder Efforts to Curb Disease in Mozambique, Official Says
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.